Navigation Links
Genitourinary Drugs: Technologies and Global Markets
Date:6/26/2012

NEW YORK, June 26, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Genitourinary Drugs: Technologies and Global Markets

http://www.reportlinker.com/p0919336/Genitourinary-Drugs-Technologies-and-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This study provides a comprehensive analysis of the market for genitourinary drugs on a global basis. Its aim is to provide a range of information, from detailed product analyses within health and wellness subsegments to overall industry trends, in order to quantify and qualify the market for drug products to treat various genitourinary diseases in both men and women. Individual drug product-types are forecast on a global basis, as are overall disease segments. Forecasts and trends are developed from a cross-reference of data points, gleaned from proprietary industry sources, company publications, industry benchmarking, and other divergent data sources to arrive at a cogent and coordinated forecast.

REASONS FOR DOING THE STUDY

For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop an effective strategy begins with where opportunity exists and ends with how to effectively execute the strategy to capture profit from opportunity.

The genitourinary disease drug market presents a significant part of the overall pharmaceutical product market worldwide. This study investigates the specific classes of genitourinary diseases and the pharmaceutical products for their treatment. Existing drug products and potential drugs in the pipelines of the major pharmaceutical players in this market are reviewed. Growing health concerns in developing countries are expected to continue to contribute substantially to market growth through the forecast period. This report analyzes emerging markets by disease category. Continued growth is expected in emerging geographies, driven by the health awareness of the growing middle class in emerging countries such as India, China, Brazil and Russia.

This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and products, strategies for accessing emerging markets, specific disease prevalence and geographies in order to allocate resources and make effective decisions.

SCOPE OF REPORT

Current and projected product forecasts during the forecast period (2011 to 2016) are discussed. New product launches will be discussed. Revenue figures for 2010 are in an actual figure, except where actual results have not been reported due to the release timing of the report.

The report includes analysis of leading and emerging drug products for each genitourinary disease. Profiles of manufacturers of leading products and their specific products are provided. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients with genitourinary diseases.

Market figures are based on revenues at the manufacturers' level and are projected at 2011-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products, and other factors affecting the market

Included in this report are forecasts by product, product category and company from 2009 through 2016. The study is arranged to offer an overview of the genitourinary disease drug market accompanied by product, company, geography and mechanism of action, with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data for each drug subsegment.

Where possible, epidemiological data is presented to underscore the importance of these diseases in the world population and the potential morbidity/mortality resulting from ineffective treatment of these diseases worldwide. Patent and clinical trial information is reviewed for various drugs. The status of approvals of drugs in each disease segment by the FDA and regulatory agencies in other countries is reviewed.

Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.

Diagnostics for each disease area and various drugs are described. However, diagnostics are not included in market figures, as they are outside of the scope of this report.

All market share data presented is on a global basis, unless specifically noted.

INTENDED AUDIENCE

This report is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, investor consultants and anyone interested in the genitourinary drug market, its products, its industry participants and its future.

The importance of identifying overall market trends, product opportunities, emerging geographies, merger and acquisition (M&A) opportunities and insights that provide guidance for sales growth or defensive moves cannot be overstated for a variety of constituents, including the following.

Established companies in the industry will benefit from the contents, including corporate strategy, sales and marketing, business development and R&D.

Emerging players in the segment must understand specific opportunities for out-licensing, originating from the elements of differentiation of their product or technology as compared to leading, competitive and emerging products. In addition, market forecasts can support investment, provided a thorough and detailed substantiation is provided for the market forecast, as is found in this study.

Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunities and risks that are being encountered in the industry, in a product and company specific analysis.

Equity analysts are provided detailed forecasts for the next five years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run.

METHODOLOGY AND INFORMATION SOURCES

In-depth interviews were conducted with leading experts in the field who are executives in companies, industry analysts and leading individuals in the field.

The genitourinary disease drug market comprises drugs for treatment of an assortment of specific diseases in both men and women. For completeness, the current and forecast markets comprise the total market opportunity for each respective segment. Within each subsection, there are detailed forecasts for each driving mechanism, or relevant area of growth.

Information to prepare this report was obtained from participating and emerging companies in the genitourinary disease area, the American Urology Association, the American Infertility Association, the National Institute of Kidney and Urological Disease (NIDDK, NIH), the National Library of Medicine (NLM, NIH) database and the U.S. Patent and Trademark Office (USPOTP). Additional information was obtained from a variety of medical and technical journals in the various specialties of the genitourinary diseases. Other sources included the New York Times, the Wall Street Journal, the Washington Post, other newspapers and company documents, and other internet websites. Population estimates are based on those reported by the International Database of the U.S. Census Bureau. Statistical data was obtained from the World Health Organization (WHO), the National Institute of Health (NIH) and the WHO Collaborating Centre for Drug Statistics Methodology (Norway).

Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.

ANALYST CREDENTIALS

Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early and mid-stage drug development.

TABLE OF CONTENTS

CHAPTER ONE: INTRODUCTION 1

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

SCOPE OF REPORT 2

INTENDED AUDIENCE 3

METHODOLOGY AND INFORMATION SOURCES 3

ANALYST CREDENTIALS 4

RELATED BCC REPORTS 4

BCC ON-LINE SERVICES 4

DISCLAIMER 5

CHAPTER TWO: SUMMARY 6

SUMMARY 6

SUMMARY TABLE MAJOR GENITOURINARY DRUG CATEGORIES

REVENUE, THROUGH 2016 ($ MILLIONS)* 7

SUMMARY FIGURE MAJOR GENITOURINARY DRUG CATEGORIES

REVENUE, 2009-2016 ($ MILLIONS)* 8

CHAPTER THREE: OVERVIEW 9

DISEASES OF THE GENITOURINARY SYSTEM 9

TABLE 1 GENITOURINARY DISEASE NAMES, GENDER AND

DESCRIPTION 9

BENIGN PROSTATIC HYPERTROPHY (BPH) 9

ERECTILE DYSFUNCTION (ED) 10

INCONTINENCE (IC) 10

OVERACTIVE BLADDER (OB) 10

HORMONAL CONTRACEPTION (HC) 11

INFERTILITY (IF) 11

INFECTION (INF) 12

DRUGS GOING OFF-PATENT IN FORECAST PERIOD 12

TABLE 2 GENITOURINARY DRUGS WITH EXPIRING PATENTS,

2010-2016 13

REVENUE PROJECTION FOR GENITOURINARY DRUGS, 2011-

2016 13

TABLE 3 FIVE-YEAR PROJECTION FOR REVENUES IN

GENITOURINARY DRUG MARKET, THROUGH 2016 ($ MILLIONS) 14

REVENUE PROJECTION FOR …(CONTINUED) 15

TOP 10 BEST-SELLING GENITOURINARY DRUGS, 2011 16

TABLE 4 TOP 10 BEST-SELLING GENITOURINARY DRUGS IN 2011

($ MILLIONS/%) 16

REVENUE BY GENITOURINARY DISEASE DRUG SEGMENT 16

TABLE 5 REVENUES BY GENITOURINARY SEGMENT, 2011 ($

MILLIONS/%) 17

REVENUE FROM GENITOURINARY DRUGS BY GEOGRAPHIC

AREA 17

TABLE 6 REVENUE FROM GENITOURINARY DRUGS BY

GEOGRAPHIC AREA, 2011 ($ MILLIONS/%) 17

REVENUE FROM GENITOURINARY…(CONTINUED) 18

CHAPTER FOUR: GENITOURINARY DISEASE CONDITIONS 19

GENITOURINARY DISEASE CONDITIONS 19

BENIGN PROSTATIC HYPERTROPHY 20

TABLE 7 MAJOR DRUGS APPROVED FOR TREATMENT OF BENIGN

PROSTATIC HYPERTROPHY 21

BENIGN PROSTATIC HYPERTROPHY (CONTINUED) 22

BENIGN PROSTATIC HYPERTROPHY (CONTINUED) 23

BENIGN PROSTATIC HYPERTROPHY (CONTINUED) 24

INCONTINENCE AND OVERACTIVE BLADDER 25

INCONTINENCE AND OVERACTIVE … (CONTINUED) 26

ERECTILE DYSFUNCTION 27

TABLE 8 PRESCRIPTION DRUGS THAT HAVE AN ED WARNING 28

TABLE 9 CURRENT DRUGS FOR ERECTILE DYSFUNCTION

TREATMENT 29

INFECTION 30

TABLE 10 COMMON BACTERIAL SPECIES IN GENITOURINARY

INFECTIONS 30

INFERTILITY 31

FEMALE INFERTILITY 31

Female Infertility (Continued) 32

MALE INFERTILITY 33

Male Infertility (Continued) 34

HORMONAL CONTRACEPTION 35

ORAL CONTRACEPTIVES 35

TABLE 11 DESIGN OF HORMONAL CONTRACEPTIVE

MEDICATIONS 36

TABLE 12 LONG-TERM CONTRACEPTIVE TREATMENTS 37

THE MORNING-AFTER PILL 37

The Morning-after Pill (Continued) (Continued) 38

CHAPTER FIVE MARKET ANALYSIS 39

MARKET OVERVIEW 39

MARKET OVERVIEW (CONTINUED) 40

MARKET SIZE AND FORECAST 41

TABLE 13 REVENUE FROM GENITOURINARY DISEASE DRUGS

FOR MAJOR COMPANIES, THROUGH 2016 ($ MILLIONS) 41

MARKET SIZE AND FORECAST (CONTINUED) 42

TABLE 14 FIVE-YEAR PROJECTION FOR REVENUE INCREASES IN

GENITOURINARY DRUG MARKET, THROUGH 2016 ($ MILLIONS) 43

CURRENT DRUGS IN THE MARKET 44

PIPELINE FORECAST FOR GENITOURINARY DRUGS 45

TABLE 15 DRUGS FOR GENITOURINARY DISEASE IN THE

PIPELINE WORLDWIDE, 2012 45

MARKET BY MECHANISM OF ACTION AND MODE OF DELIVERY 45

CHAPTER SIX: BENIGN PROSTATIC HYPERTROPHY (BPH) 46

OVERVIEW 46

ETIOLOGY OF BENIGN PROSTATIC HYPERTROPHY 46

ETIOLOGY OF BENIGN PROSTATIC … (CONTINUED) 47

DIAGNOSIS, TREATMENT AND MANAGEMENT 48

DRUGS BY MECHANISM OF ACTION 49

TABLE 16 MECHANISM OF ACTION OF APPROVED DRUGS FOR

BPH TREATMENT 49

DRUGS BY MECHANISM OF ACTION (CONTINUED) 50

DRUGS BY MECHANISM OF ACTION (CONTINUED) 51

D-3263 VERSUS SIPULEUCEL-T: 52

PROVENGE (SIPULEUCEL-T) MOA: 52

EPIDEMIOLOGY AND STATISTICS DATA 52

INCIDENCE OF BPH 53

TABLE 17 PERCENTAGE OF MALES (OVER FIFTY) WITH BPH AND

EXHIBITING SYMPTOMS, 2010 (MILLIONS) 54

TABLE 18 PROJECTED INCREASE IN MEN WITH SYMPTOMATIC

BPH, THROUGH 2016 (MILLIONS) 54

MANAGEMENT OF BPH 55

MECHANISM OF ACTION OF BPH DRUGS 55

MECHANISM OF ACTION OF BPH DRUGS (CONTINUED) 56

TABLE 19 MECHANISM OF ACTION OF APPROVED DRUGS FOR

BPH TREATMENT 57

MARKET ANALYSIS: REVENUES AND FORECAST 57

TABLE 20 BENIGN PROSTATIC HYPERTROPHY DRUG REVENUES,

THROUGH 2016 ($ MILLIONS) 58

TABLE 21 REVENUES FROM THE MAJOR BPH DRUGS, THROUGH

2016 ($ MILLIONS) 59

TABLE 22 PROJECTED REVENUES FOR BPH DRUGS BY REGION,

THROUGH 2016 ($ MILLIONS) 59

BPH DRUG SALES BY MECHANISM OF ACTION 60

TABLE 23 REVENUE FROM BPH DRUGS BY MECHANISM OF

ACTION, THROUGH 2016 ($ MILLIONS) 60

MAJOR PLAYERS IN BPH MARKET 61

TABLE 24 MAJOR PLAYERS IN BPH MARKET IN 2011 ($ MILLIONS) 61

MAJOR BPH DRUG PROFILES 61

TABLE 25 PROFILE OF ALPHA-BLOCKER DRUGS 62

TABLE 26 PROFILE OF 5-ALPHA-REDUCTASE INHIBITOR DRUGS 62

TABLE 27 PROFILE OF DRUGS WITH ALTERNATIVE MECHANISM

OF ACTION 63

THE PIPELINE FOR BENIGN PROSTATIC HYPERTROPHY

DRUGS IN PRECLINICAL DEVELOPMENT 63

TABLE 28 DRUG FOR BPH PRECLINICAL TRIALS 64

TABLE 28 (CONTINUED) 65

TABLE 28 (CONTINUED) 66

TABLE 28 (CONTINUED) 67

TABLE 28 (CONTINUED) 68

BPH DRUGS IN PHASE I CLINICAL TRIALS 68

TABLE 29 BPH DRUGS IN PHASE I CLINICAL TRIALS 69

TABLE 29 (CONTINUED) 70

BPH DRUGS IN PHASE II CLINICAL TRIALS 71

TABLE 30 DRUGS IN PHASE II CLINICAL TRIALS FOR BPH

TREATMENT 71

TABLE 30 (CONTINUED) 72

DRUGS IN PHASE III CLINICAL TRIALS FOR BPH

TREATMENT 72

TABLE 31 DRUGS IN PHASE III CLINICAL TRIALS FOR BPH

TREATMENT 73

BPH DRUGS PENDING FDA APPROVAL 73

TABLE 32 BPH DRUGS PENDING APPROVAL FROM U S FDA 74

DRUGS APPROVED BY THE FDA IN 2011 75

TABLE 33 FDA APPROVED DRUGS FOR BPH TREATMENT IN 2011 75

Drugs Approved by the FDA in 2011 (Continued) 76

CHAPTER SEVEN: ERECTILE DYSFUNCTION 77

OVERVIEW 77

ETIOLOGY OF ERECTILE DYSFUNCTION 78

NONSTEROIDAL ANTI-INFLAMMATORY DRUGS DRUGS

BY MECHANISM OF ACTION (CONTINUED) 79

DIAGNOSIS, TREATMENT AND MANAGEMENT 79

MECHANISM OF ACTION 80

EPIDEMIOLOGICAL AND STATISTICAL DATA 80

INCIDENCE OF ERECTILE DYSFUNCTION 81

TABLE 34 PROJECTED INCREASE IN ERECTILE DYSFUNCTION,

THROUGH 2016 (MILLIONS) 81

MECHANISM OF ACTION 82

TABLE 35 CURRENT DRUGS FOR ERECTILE DYSFUNCTION

TREATMENT 82

MARKET ANALYSIS AND FORECAST 83

TABLE 36 REVENUES FOR ERECTILE DYSFUNCTION DRUGS,

THROUGH 2016 ($ MILLIONS) 83

REGIONAL FORECAST FOR ED REVENUES 84

TABLE 37 FORECAST REVENUE INCREASE FROM ERECTILE

DYSFUNCTION DRUGS, THROUGH 2016 ($ MILLIONS) 84

TABLE 38 REVENUES AND MARKET SHARE APPROVED ERECTILE

DYSFUNCTION DRUGS, 2011 AND 2016 ($ MILLIONS/%) 84

DRUG REVENUES BY MECHANISM OF ACTION 85

MAJOR PLAYERS IN THE ERECTILE DYSFUNCTION MARKET 85

TABLE 39 MAJOR COMPANIES IN THE ERECTILE DYSFUNCTION

DRUG MARKET, 2011 ($ MILLIONS/%) 86

PROFILE OF ERECTILE DYSFUNCTION DRUGS 86

TABLE 40 ERECTILE DYSFUNCTION DRUG PROFILES 86

ERECTILE DYSFUNCTION DRUG PIPELINE 87

DRUGS IN PRECLINICAL DEVELOPMENT STAGE 87

TABLE 41 DRUGS IN PRECLINICAL DEVELOPMENT 87

Drugs in Preclinical … (Continued) 88

DRUGS IN PHASE I CLINICAL TRIALS 89

TABLE 42 ERECTILE DYSFUNCTION DRUGS IN PHASE I CLINICAL

TRIAL 89

DRUGS IN PHASE II CLINICAL TRIALS 90

TABLE 43 ERECTILE DYSFUNCTION DRUGS IN PHASE II

CLINICAL TRIALS 90

TABLE 43 (CONTINUED) 91

Drugs in Phase II Clinical Trials (Continued) 92

DRUGS IN PHASE III CLINICAL TRIALS 93

TABLE 44 ERECTILE DYSFUNCTION DRUGS IN PHASE III

CLINICAL TRIALS 93

TABLE 44 (CONTINUED) 94

ERECTILE DYSFUNCTION DRUGS PENDING FDA

APPROVAL 95

TABLE 45 ERECTILE DYSFUNCTION DRUGS PENDING FDA

APPROVAL 95

Erectile Dysfunction Drugs Pending … (Continued) 96

CHAPTER EIGHT: URINARY INCONTINENCE AND OVERACTIVE

BLADDER 97

OVERVIEW 97

STRESS INCONTINENCE 98

URGE INCONTINENCE 98

OVERFLOW INCONTINENCE 98

MIXED INCONTINENCE 98

FUNCTIONAL INCONTINENCE 99

TOTAL INCONTINENCE 99

DIAGNOSIS, TREATMENT AND MANAGEMENT 99

TABLE 46 DRUGS FOR TREATMENT OF INCONTINENCE AND

OVERACTIVE BLADDER 100

DRUG REVENUE BY MECHANISM OF ACTION 101

EPIDEMIOLOGY AND STATISTICAL DATA 102

INCIDENCE OF INCONTINENCE AND OVERACTIVE

BLADDER 102

TABLE 47 INCIDENCE OF INCONTINENCE AND OVERACTIVE

BLADDER 102

MARKET ANALYSIS: SALES AND FORECASTS 103

TABLE 48 GLOBAL REVENUES FOR INCONTINENCE AND

OVERACTIVE BLADDER DRUGS, THROUGH 2016 ($ MILLIONS) 103

THE U S MARKET FOR INCONTINENCE AND OVERACTIVE

BLADDER DRUGS 104

TABLE 49 THE U S AND EUROPEAN MARKETS FOR

INCONTINENCE/OVERACTIVE BLADDER DRUGS, THROUGH

2016 ($ MILLIONS) 104

REVENUE FROM IC/OB DRUGS BY COUNTRY OR REGION 105

TABLE 50 REVENUES FROM IC/OB DRUGS BY COUNTRY OR

REGION, THROUGH 2016 ($ MILLIONS) 105

MAJOR PLAYERS IN THE INCONTINENCE OVERACTIVE

BLADDER DRUG SEGMENT 105

TABLE 51 MAJOR PLAYERS IN THE U S INCONTINENCE AND

OVERACTIVE BLADDER DRUG MARKET BY MARKET SHARE,

2011 ($ MILLIONS/%) 105

PROFILE OF THE APPROVED IC/OB DRUGS 106

TABLE 52 PROFILE OF THE FDA APPROVED IC/OB DRUGS ON THE

MARKET 106

TABLE 53 PROFILE OF THE FDA APPROVED IC/OB DRUGS ON THE

MARKET 106

COMPANY PIPELINES FOR INCONTINENCE/OVERACTIVE

BLADDER DRUGS 107

PIPELINE DRUGS FOR IC IN PRECLINICAL

DEVELOPMENT PHASE 107

TABLE 54 URINARY INCONTINENCE DRUGS IN PRECLINICAL

DEVELOPMENT 107

TABLE 54 (CONTINUED) 108

PIPELINE DRUGS FOR IC IN PHASE I CLINICAL TRIALS 109

TABLE 55 PIPELINE DRUGS FOR IC IN PHASE I CLINICAL TRIALS 109

PIPELINE DRUGS FOR IC IN PHASE II CLINICAL TRIALS 109

TABLE 56 PIPELINE DRUGS FOR IC IN PHASE II CLINICAL TRIALS 110

PIPELINE DRUGS FOR OVERACTIVE BLADDER 111

PIPELINE FOR OVERACTIVE BLADDER DRUGS IN

PRECLINICAL DEVELOPMENT 111

TABLE 57 PIPELINE FOR OVERACTIVE BLADDER DRUGS IN

PRECLINICAL DEVELOPMENT 111

TABLE 57 (CONTINUED) 112

PIPELINE FOR OB DRUGS IN PHASE I CLINICAL TRIALS 113

TABLE 58 PIPELINE FOR OB DRUGS IN PHASE I CLINICAL TRIALS 113

TABLE 58 (CONTINUED) 114

PIPELINE FOR OB DRUGS IN PHASE II CLINICAL TRIALS 115

TABLE 59 PIPELINE FOR OB DRUGS IN PHASE II CLINICAL

TRIALS 115

TABLE 59 (CONTINUED) 116

TABLE 59 (CONTINUED) 117

PIPELINE FOR OB DRUGS IN PHASE III CLINICAL TRIALS 118

TABLE 60 PIPELINE FOR OB DRUGS IN PHASE III TRIALS 118

TABLE 60 (CONTINUED) 119

PIPELINE FOR OB DRUGS IN PENDING FDA APPROVAL 120

TABLE 61 PIPELINE FOR OB DRUGS PENDING FDA APPROVAL 120

TABLE 61 (CONTINUED) 121

Pipeline for OB Drugs in … (Continued) 122

CHAPTER NINE: INFERTILITY 123

INFERTILITY OVERVIEW 123

DIAGNOSIS, TREATMENT AND MANAGEMENT 124

TABLE 62 CAUSES OF INFERTILITY IN WOMEN AND MEN 125

FEMALE INFERTILITY 125

MALE INFERTILITY 126

Male Infertility (Continued) 127

Male Infertility (Continued) 128

INFERTILITY DRUGS BY MECHANISM OF ACTION 129

TABLE 63 INFERTILITY DRUGS BY MECHANISM OF ACTION 129

EPIDEMIOLOGICAL AND STATISTICAL DATA 129

INCIDENCE OF INFERTILITY 130

TABLE 64 PROJECTED INCIDENCE OF INFERTILITY FOR THE

PERIOD, THROUGH 2016 131

MARKET ANALYSIS: SALES AND FORECAST 131

TABLE 65 REVENUES FROM INFERTILITY DRUGS, THROUGH 2016

($ MILLIONS) 132

SALES BY MECHANISM OF ACTION 133

TABLE 66 MECHANISM OF ACTION OF INFERTILITY DRUGS BY

2011 REVENUE (%) 133

MAJOR PLAYERS IN THE INFERTILITY MARKET 133

TABLE 67 MAJOR PLAYERS IN THE INFERTILITY DRUG MARKET 134

INFERTILITY DRUG PROFILES 134

TABLE 68 PROFILES OF COMMON INFERTILITY DRUGS 135

TABLE 69 PROFILE OF COMMON INFERTILITY DRUGS 135

TABLE 70 PROFILE OF COMMON INFERTILITY DRUGS 136

PIPELINE FOR INFERTILITY DRUGS 136

INFERTILITY DRUGS IN PHASE I OR PHASE II CLINICAL

TRIALS 136

TABLE 71 INFERTILITY DRUGS IN PHASE I OR PHASE II CLINICAL

TRIALS 137

INFERTILITY DRUGS IN PHASE II OR PHASE III CLINICAL

TRIALS 137

TABLE 72 INFERTILITY DRUGS IN PHASE II OR PHASE III

CLINICAL TRIALS 138

MALE INFERTILITY DRUGS IN PHASE I OR PHASE II

CLINICAL TRIALS 138

TABLE 73 MALE INFERTILITY DRUGS IN PHASE I OR PHASE II

CLINICAL TRIALS 139

Male Infertility Drugs in Phase I… (Continued) 140

CHAPTER TEN: HORMONAL CONTRACEPTION 141

OVERVIEW 141

ETIOLOGY OF HORMONAL CONTRACEPTION 141

ORAL CONTRACEPTIVES 142

TABLE 74 DOSING SCHEDULES OF HORMONAL CONTRACEPTIVE

MEDICATIONS 143

TABLE 75 SUMMARY OF LONG-TERM CONTRACEPTIVE

TREATMENTS 144

THE MORNING-AFTER PILL 144

EPIDEMIOLOGY AND STATISTICAL DATA 145

INCIDENCE OF HORMONAL CONTRACEPTIVE USE 146

TABLE 76 USE OF HORMONAL CONTRACEPTIVE METHODS IN

SELECTED COUNTRIES (THOUSANDS) 146

MARKET ANALYSIS AND FORECAST 146

TABLE 77 REVENUES FROM HORMONAL CONTRACEPTION

DRUGS, THROUGH 2016 ($ MILLIONS) 147

REVENUE FOR HORMONAL CONTRACEPTION BY COUNTRY 148

TABLE 78 REVENUE FOR HORMONAL CONTRACEPTION BY

COUNTRY/REGION, THROUGH 2016 ($ MILLIONS) 148

MAJOR PLAYERS IN HORMONAL CONTRACEPTION DRUGS 148

TABLE 79 MAYOR PLAYERS IN THE HORMONAL CONTRACEPTION

MARKET 148

TABLE 79 (CONTINUED) 149

TABLE 80 REVENUES OF MAJOR PLAYERS IN THE HORMONAL

CONTRACEPTION MARKET, THROUGH 2016 ($ MILLIONS) 149

TABLE 81 PROFILE FOR COMMON DRUGS FOR HORMONAL

CONTRACEPTION 150

TABLE 82 PROFILE FOR COMMON DRUGS FOR HORMONAL

CONTRACEPTION 150

PIPELINE FOR HORMONAL CONTRACEPTION DRUGS 150

PIPELINE FOR HC DRUGS IN DEVELOPMENT, PHASE I, II

CLINICAL TRIALS 151

TABLE 83 HC DRUGS IN DEVELOPMENT, PHASE I, II CLINICAL

TRIALS 151

TABLE 83 (CONTINUED) 152

PIPELINE FOR HC DRUGS IN PHASE III CLINICAL TRIAL 153

TABLE 84 PIPELINE FOR HC DRUGS IN PHASE III CLINICAL

TRIALS 153

TABLE 84 (CONTINUED) 154

TABLE 84 (CONTINUED) 155

PIPELINE FOR HC DRUGS PENDING FDA APPROVAL 155

TABLE 85 PIPELINE FOR HC DRUGS PENDING FDA APPROVAL 156

Pipeline for HC Drugs Pending FDA approval (Continued) 157

CHAPTER ELEVEN: GENITOURINARY INFECTION 158

OVERVIEW 158

TABLE 86 COMMON BACTERIAL SPECIES IN GENITOURINARY

INFECTIONS 159

MARKET ANALYSIS AND FORECAST 160

TABLE 87 TYPICAL BACTERIA CAUSING GENITOURINARY

INFECTION AND ANTIBIOTICS FOR THEIR TREATMENT 160

MAJOR PLAYERS IN ANTIBIOTICS MARKET 161

TABLE 88 GENITOURINARY INFECTIONS AND THE ANTIBIOTICS

USED FOR TREATMENT 161

CHAPTER TWELVE: GLOBAL GENITOURINARY DISEASE DRUG

MARKET 162

OVERVIEW 162

GLOBAL REVENUES FROM GENITOURINARY DRUGS 162

TABLE 89 GLOBAL REVENUES FROM GENITOURINARY DRUGS,

THROUGH 2016, ($ MILLIONS) 162

GLOBAL INCONTINENCE AND OVERACTIVE BLADDER

REVENUE 163

TABLE 90 GLOBAL INCONTINENCE AND OVERACTIVE BLADDER

REVENUE FORECAST, THROUGH 2016 ($ MILLIONS) 163

GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUG

REVENUES 164

TABLE 91 GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUG

REVENUES, THROUGH 2016 ($ MILLIONS) 164

GLOBAL REVENUES FROM ERECTILE DYSFUNCTION

DRUGS 164

TABLE 92 GLOBAL REVENUES FROM ERECTILE DYSFUNCTION

DRUGS, THROUGH 2016 ($ MILLIONS) 165

GLOBAL REVENUE FROM HORMONAL CONTRACEPTION 165

TABLE 93 PROJECTED GLOBAL REVENUE FROM HORMONAL

CONTRACEPTION, THROUGH 2016 ($ MILLIONS) 165

GLOBAL REVENUE FROM INFERTILITY DRUGS 166

TABLE 94 GLOBAL REVENUE FROM INFERTILITY DRUGS,

THROUGH 2016 ($ MILLIONS) 166

GENITOURINARY DRUGS ONLY AVAILABLE IN SPECIFIC

COUNTRIES 167

BENIGN PROSTATIC HYPERTROPHY DRUGS AVAILABLE

IN CHINA 167

TABLE 95 BPH DRUGS ONLY AVAILABLE IN CHINA 167

ERECTILE DYSFUNCTION DRUGS AVAILABLE IN INDIA 167

TABLE 96 ERECTILE DYSFUNCTION DRUGS AVAILABLE ONLY IN

INDIA 168

CHAPTER THIRTEEN: PATENT EXAMPLES FOR GENITOURINARY

DRUGS 169

TABLE 97 U S PATENTS FOR GENITOURINARY DRUGS 169

TABLE 97 (CONTINUED) 170

CHAPTER FOURTEEN: COMPANY PROFILES 171

AGILE THERAPEUTICS 171

PRODUCTS 171

STRATEGY 172

ALLERGAN INC 172

PRODUCTS 172

STRATEGY 173

ANTARES PHARMA INC 173

PRODUCTS 173

STRATEGY 174

ASTELLAS PHARMACEUTICALS US INC 174

PRODUCTS 174

STRATEGY 175

BAYER HEALTHCARE PHARMACEUTICALS 175

PRODUCTS 176

STRATEGY 176

BOEHRINGER-INGELHEIM GMBH 176

PRODUCTS 177

STRATEGY 177

DONG-A PHARMACEUTICAL CO LTD 177

PRODUCTS 178

STRATEGY 178

ELI LILLY COMPANY 178

PRODUCTS 179

STRATEGY 179

ENDO LABORATORIES 179

PRODUCTS 179

STRATEGY 180

FERRING PHARMACEUTICALS S A 180

PRODUCTS 181

STRATEGY 181

GLAXOSMITHKLINE 181

PRODUCTS 182

STRATEGY 182

KISSEI PHARMACEUTICAL CO LTD 183

PRODUCTS 183

MERCK & CO 183

PRODUCTS 184

TABLE 98 MERCK & CO, GENITOURINARY DRUG PRODUCTS 184

STRATEGY 184

MERCK SERONO S A 185

PRODUCTS 185

STRATEGY 186

NOVARTIS INTERNATIONAL AG 186

PRODUCTS 187

TABLE 99 WOMEN'S HEALTH PRODUCTS FROM NOVARTIS 187

STRATEGY 188

NYMOX PHARMACEUTICAL CORPORATION 188

PRODUCTS 188

PFIZER CORPORATION 189

PRODUCTS 189

STRATEGY 190

PREGLEM S A 190

PRODUCTS 191

STRATEGY 191

RECORDATI S P A 192

PRODUCTS 192

ROTTAPHARM SPA 192

PRODUCTS 193

TEVA PHARMACEUTICALS INDUSTRIES LTD 193

PRODUCTS 194

STRATEGY 194

VIVUS PHARMACEUTICALS INC 194

PRODUCTS 195

STRATEGY 195

WARNER-CHILCOTT PLC 195

PRODUCTS 196

TABLE 100 WARNER CHILCOTT PRODUCTS FOR WOMEN'S

HEALTH 196

STRATEGY 197

WATSON PHARMACEUTICALS 197

PRODUCTS 197

STRATEGY 198

To order this report: Drug and Medication Industry: Genitourinary Drugs: Technologies and Global Markets

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Antithrombotic/Anticoagulant Drugs: World Market 2012-2022
2. Ophthalmic Drugs: World Market Prospects 2012-2022
3. Acuo Technologies Chosen for Large Multi-Hospital VNA Contract in the U.K.
4. Vocollect Healthcare Systems And Prime Care Technologies Bring AccuNurse Key Performance Metrics To Long-Term Care Providers Via primeVIEW Digital Dashboard
5. Drug Discovery Technologies Market Soars to $79 billion by 2017, Driven by Innovations in Pipeline and Tools Development
6. Freedom Innovations Wins the American Technology Award for Health & Medical Technologies
7. SIGA Technologies Files Notice of Appeal in PharmAthene Litigation
8. Life Technologies and Cellular Dynamics International Partner for Global Commercialization of Novel Stem Cell Technologies
9. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
10. IDEV Technologies Introduces SurePathâ„¢ Guidewires
11. Acuo Technologies Grows European Business and Achieves Successful Connectathon Results in Bern, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):